Predictive and prognostic molecular markers in outcome of esophageal cancer

Diseases of the Esophagus

Volumn 19, Issue 6, 2006, Pages 425-432

  Vallbohmer D ^a   Lenz, Heinz Josef ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

(Neo ) adjuvant (radio ) chemotherapy; Esophageal cancer; Predictive and prognostic molecular markers

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CD147 ANTIGEN; CETUXIMAB; CISPLATIN; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GELATINASE A; GELATINASE B; GROWTH FACTOR RECEPTOR; IRINOTECAN; KI 67 ANTIGEN; MATRILYSIN; MOLECULAR MARKER; OXALIPLATIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P21; PROTEIN P27; PROTEIN P53; SURVIVIN; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL TRIAL; DNA REPAIR; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EXCISION REPAIR; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; DNA REPAIR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; GENES, P53; HUMANS; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PROGNOSIS; RECEPTORS, GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33750454439     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00622.x     Document Type: Review

References (57)

1. Wei J T, Shaheen N. The changing epidemiology of esophageal adenocarcinoma. Semin Gastrointest Dis 2003; 14: 112-27.
2. Crew K D, Neugut A I. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 450-64.
3. Pohl H, Welch H G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-6.
4. Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
5. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
6. Greer S E, Goodney P P, Sutton J E, Birkmeyer J D. Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 2005; 137: 172-7.
7. Zacherl J, Sendler A, Stein H J et al. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg 2003; 27: 1067-74.
8. Brucher B L, Stein H J, Zimmermann F et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004; 30: 963-71.
9. Bonner R F, Emmert-Buck M, Cole K et al. Laser capture microdissection: molecular analysis of tissue. Science 1997; 278: 1481-3.
10. Lehmann U, Bock O, Glockner S, Kreipe H. Quantitative molecular analysis of laser-microdissected paraffin-embedded human tissues. Pathobiology 2000; 68: 202-8.
11. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-65.
12. Miyazono F, Metzger R, Warnecke-Eberz U et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004; 91: 666-72.
13. Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003; 57: 1323-7.
14. Kulke M H, Odze R D, Mueller J D, Wang H, Redston M, Bertagnolli M M. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 2004; 127: 1579-86.
15. Xi H, Baldus S E, Warnecke-Eberz U et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005; 11: 8341-7.
16. Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann E H, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002; 21: 657-63.
17. Shimada H, Hoshino T, Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002; 86: 552-7.
18. Lowe S W, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
19. Shimada Y, Watanabe G, Yamasaki S et al. Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer 2000; 36: 987-93.
20. Kitamura K, Saeki H, Kawaguchi H et al. Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology 2000; 47: 419-23.
21. Nakashima S, Natsugoe S, Matsumoto M et al. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res 2000; 20: 1933-7.
22. Sohda M, Ishikawa H, Masuda N et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 2004; 110: 838-44.
23. Heeren P A, Kloppenberg F W, Hollema H, Mulder N H, Nap R E, Plukker J T. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004; 24: 2579-83.
24. Warnecke-Eberz U, Metzger R, Miyazono F et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathol response neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004; 10: 3794-9.
25. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-304.
26. Metzger R, Leichman C G, Danenberg K D et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-16.
27. Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95: 92-5.
28. Warnecke-Eberz U, Hokita S, Xi H et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Report 2005; 13: 1241-6.
29. Gibault L, Metges J P, Conan-Charlet V et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005; 93: 107-15.
30. Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 1999; 29: 493-503.
31. Gibson M K, Abraham S C, Wu T T et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-8.
32. Kuo K T, Chow K C, Wu Y C. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg 2003; 76: 909-14.
33. Han B, Liu J, Ma M J, Zhao L. Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer. World J Gastroenterol 2005; 11: 2188-92.
34. Aloia T A, Harpole D H Jr, Reed C E et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001; 72: 859-66.
35. Fukai Y, Fukuchi M, Masuda N et al. Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 2003; 104: 161-6.
36. Kleespies A, Guba M, Jauch K W, Bruns C J. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87: 95-104.
37. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79: 206-13.
38. Shih C H, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000; 6: 1161-8.
39. Shimada H, Takeda A, Nabeya Y et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 663-9.
40. Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K. Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 2003; 27: 584-9.
41. Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 1999; 86: 1396-405.
42. Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N. Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer. Ann Thorac Surg 2000; 70: 913-7.
43. Makoto O, Takeda A, Ting-Leig L et al. Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep 2002; 9: 23-8.
44. Kuwahara M, Hirai T, Yoshida K et al. p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus 1999; 12: 116-19.
45. Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 1999; 57: 311-17.
46. Shamma A, Doki Y, Tsujinaka T et al. Loss of p27 (KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 2000; 58: 152-8.
47. Terashita Y, Ishiguro H, Haruki N et al. Excision repair cross complementing 3 expression is involved in patient prognosis and tumor progression in esophageal cancer. Oncol Rep 2004; 12: 827-31.
48. Joshi M B, Shirota Y, Danenberg K D et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11: 2215-21.
49. Ikeguchi M, Maeta M, Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int J Mol Med 2001; 7: 413-17.
50. Sturm I, Petrowsky H, Volz R. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: High BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 2001; 19: 2272-81.
51. Takayama T, Nagao M, Sawada H et al. Bcl-X expression in esophageal squamous cell carcinoma: Association with tumor progression and prognosis. J Surg Oncol 2001; 78: 116-23.
52. Matsumoto M, Natsugoe S, Nakashima S et al. Clinical significance and prognostic value of apoptosis related proteins in superficial esophageal squamous cell carcinoma. Ann Surg Oncol 2001; 8: 598-604.
53. Tanioka Y, Yoshida T, Yagawa T et.al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003; 89: 2116-21.
54. Ishibashi Y, Matsumoto T, Niwa M et.al. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004; 101: 1994-2000.
55. Sharma R, Chattopadhyay T K, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology 2004; 67: 300-9.
56. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
57. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.